Design and validation of an immuno-PCR assay for IFN-α2b quantification in human plasma
Aim: Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus. An immuno-PCR (iPCR) was developed to quantify low amounts of IFN-α in human plasma followed by a deep analysis of the methodologic robustness throughout quality by design approach. Results: An accurate, sensitive, selective and versatile iPCR was validated. The critical iPCR procedural steps were identified, applying a Plackett-Burman design. Also, this assay demonstrated an outstanding LOD of 0.3 pg/ml. A significant aspect relies on its high versatility to detect and quantify other cytokines in human plasma as the appropriate biotinylated antibody is employed. Conclusion: This reliable iPCR assay can be clinically used as an alternative method for quantitating and detecting low IFN-α2b concentrations in human plasma samples.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 23 vom: 20. Dez., Seite 2175-2188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Attallah, Carolina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Accuracy |
|---|
| Anmerkungen: |
Date Completed 27.04.2020 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2019-0225 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303278412 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303278412 | ||
| 003 | DE-627 | ||
| 005 | 20231225112503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2019-0225 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1010.xml |
| 035 | |a (DE-627)NLM303278412 | ||
| 035 | |a (NLM)31724446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Attallah, Carolina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design and validation of an immuno-PCR assay for IFN-α2b quantification in human plasma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus. An immuno-PCR (iPCR) was developed to quantify low amounts of IFN-α in human plasma followed by a deep analysis of the methodologic robustness throughout quality by design approach. Results: An accurate, sensitive, selective and versatile iPCR was validated. The critical iPCR procedural steps were identified, applying a Plackett-Burman design. Also, this assay demonstrated an outstanding LOD of 0.3 pg/ml. A significant aspect relies on its high versatility to detect and quantify other cytokines in human plasma as the appropriate biotinylated antibody is employed. Conclusion: This reliable iPCR assay can be clinically used as an alternative method for quantitating and detecting low IFN-α2b concentrations in human plasma samples | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a ELISA | |
| 650 | 4 | |a IFN-α | |
| 650 | 4 | |a accuracy | |
| 650 | 4 | |a immuno-PCR | |
| 650 | 4 | |a linear range | |
| 650 | 4 | |a precision | |
| 650 | 4 | |a quality by design | |
| 650 | 4 | |a robustness | |
| 650 | 4 | |a selectivity | |
| 650 | 4 | |a sensitivity | |
| 650 | 7 | |a Interferon alpha-2 |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Interferon-alpha2b |2 NLM | |
| 700 | 1 | |a Rodríguez, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Etcheverrigaray, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Oggero, Marcos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 11(2019), 23 vom: 20. Dez., Seite 2175-2188 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:23 |g day:20 |g month:12 |g pages:2175-2188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2019-0225 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 23 |b 20 |c 12 |h 2175-2188 | ||